Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chroinc Pain
- Sponsor
- Weibing Miao, PhD
- Enrollment
- 60
- Primary Endpoint
- Standardized Uptake Value
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
Chronic pain is a major public health issue, which seriously affects patients' quality of life. Neuroinflammation is an important mechanism resulting in chronic pain. Translocator protein (TSPO) has served as a marker of microglial activation and neuroinflammation. 18F-DPA714, a tracer targeted TSPO, can be used to evaluate the microglial activation and neuroinflammation in vivo by PET imaging.Recent and increasing studies have found changes in TSPO and its ligands in various chronic pain models. Reversing their expressions has been shown to alleviate chronic pain in these models, illustrating the effects of TSPO and its ligands.The investigators aim to explore the clinical feasibility used 18F-DPA714 PET imaging to monitor microglial cells activation of center nervous system in chronic pain patients. This study might reveal significant neuroinflammatory process in the center nervous system of the chronic pain patients. The results of this study might provide a new biomarker of disease pathological progression and indicates that TSPO-based therapy may become an alternative strategy for treating chronic pain.
Investigators
Weibing Miao, PhD
professor
First Affiliated Hospital of Fujian Medical University
Eligibility Criteria
Inclusion Criteria
- •chronic pain patients
- •Written informed consent was provided by the patients and their family
Exclusion Criteria
- •history of head trauma , epilepsy, claustrophobia, rheumatic or autoimmune diseases, psychiatric disorders, severe somatic diseases (neurological,cardiovascular, etc.),previous heart or brain surgery, substance abuse, inability to refrain from hypnotics, magnetic implants, pregnancy, lactation
Outcomes
Primary Outcomes
Standardized Uptake Value
Time Frame: 2 years
Measures of specific binding of 18F-DPA-714 measures of specific binding of the tracer